ZA964193B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA964193B
ZA964193B ZA964193A ZA964193A ZA964193B ZA 964193 B ZA964193 B ZA 964193B ZA 964193 A ZA964193 A ZA 964193A ZA 964193 A ZA964193 A ZA 964193A ZA 964193 B ZA964193 B ZA 964193B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA964193A
Inventor
Lawrence John Penkler
Darryl Vanstone Whittaker
Original Assignee
Farmarc Nederland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmarc Nederland Bv filed Critical Farmarc Nederland Bv
Publication of ZA964193B publication Critical patent/ZA964193B/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA964193A 1995-06-13 1996-05-24 Pharmaceutical composition ZA964193B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA954885 1995-06-13

Publications (1)

Publication Number Publication Date
ZA964193B true ZA964193B (en) 1996-12-04

Family

ID=25585147

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964193A ZA964193B (en) 1995-06-13 1996-05-24 Pharmaceutical composition

Country Status (3)

Country Link
AU (1) AU5774796A (en)
WO (1) WO1996041646A2 (en)
ZA (1) ZA964193B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA156496A (en) * 1996-09-03 1997-10-15 Nycomed Austria Gmbh PHARMACEUTICAL COMPOSITION
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
MXPA04007328A (en) * 2002-02-01 2005-07-05 Shimoda Biotech Pty Ltd Pharmaceutical composition.
ES2287658T3 (en) * 2004-03-10 2007-12-16 Shimoda Biotech (Pty) Ltd STABLE INJECTABLE COMPOSITIONS OF DICLOFENAC.
KR20170123724A (en) 2006-03-28 2017-11-08 자블린 파머슈티칼스 인코포레이티드 Formulations of low dose diclofenac and beta-cyclodextrin
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
UY38431A (en) * 2018-10-31 2020-05-29 Servier Lab CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2190598A1 (en) * 1994-05-27 1995-12-07 Lawrence John Penkler Pharmaceutical composition
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
WO1996041646A3 (en) 1997-02-13
WO1996041646A2 (en) 1996-12-27
AU5774796A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
HU9601698D0 (en) Pharmaceutical composition
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
ZA967827B (en) Pharmaceutical compositions
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
ZA96525B (en) Novel pharmaceutical compositions
ZA9610426B (en) Pharmaceutical composition
ZA961051B (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
HUP9602822A2 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
GB9514807D0 (en) Pharmaceutical composition
ZA961735B (en) Pharmaceutical composition
GB9507038D0 (en) Pharmaceutical composition
GB9507037D0 (en) Pharmaceutical composition
GB9515207D0 (en) Pharmaceutical composition
GB9515208D0 (en) Pharmaceutical composition
HU9903430D0 (en) Pharmaceutical composition
ZA9510132B (en) Pharmaceutical composition